Ocugen, Inc. reported $5.4M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $5.4M (to Q3 2025). Net income: −$82M, trailing twelve months to Q2 2026. Free cash flow: −$61M, trailing twelve months to Q2 2026. Operating margin: −1200%, trailing twelve months to Q3 2025.

OCGNOcugen, Inc.

Healthcare

$0.98-44% 1Y

$0.98

$0.9852 weeks$2.48

Latest close: a new 52-week lowOct 8, 2026what changed →

OCGN as reported

Ocugen, Inc. reported $5.4M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$5.4M

Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied

Net income: −$82M
Net income · +44% year on year · trailing twelve months to Q2 2026
Free cash flow: −$61M
Free cash flow · +17% year on year · trailing twelve months to Q2 2026
Operating margin: −1200%
Operating margin · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for OCGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$5.4M	n/a	Q3 2025
Net income	−$82M	+44%	Q2 2026
EPS	−$0.18	n/a	Q2 2024 · 8 quarters behind
Operating margin	−1200%	n/a	Q3 2025
Net margin	−1268%	n/a	Q3 2025
ROE	−499%	n/a	Q2 2026
ROA	−115%	n/a	Q2 2026
ROIC	1476%	n/a	Q2 2026
Free cash flow	−$61M	+17%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.